While pharmaceutical giant GlaxoSmithKline is laying off employees in an ongoing restructuring of its research and development – the Triangle's 2,600 employees appear to be outside the focus of that effort.
GSK has laid off employees at its two major R&D hubs – Collegeville, Pa., and Stevenage in the U.K.
The move comes months after its new R&D head Hal Barron announced a new strategy for his unit, prioritizing innovation and moving towards delivering a pipeline of medicines with a focus…
